Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BAY 2395840 in Japanese Healthy Males
NCT05563454Phase 1Completed
- Sponsor
- Bayer
- Start
- Oct 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of fulmetibant in diabetic neuropathy (5 arms), sponsored by Bayer. Primary endpoint: Incidence of Treatment Emergent Adverse Events. Started Oct 2022; status: completed.
02
Drugs
fulmetibant
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT05563454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05563454.